Brokerages Expect Puma Biotechnology, Inc. (NASDAQ:PBYI) Will Post Earnings of $0.33 Per Share

Share on StockTwits

Equities research analysts forecast that Puma Biotechnology, Inc. (NASDAQ:PBYI) will announce earnings per share (EPS) of $0.33 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Puma Biotechnology’s earnings, with the lowest EPS estimate coming in at $0.26 and the highest estimate coming in at $0.39. Puma Biotechnology posted earnings of ($0.43) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 176.7%. The firm is expected to issue its next earnings results on Thursday, May 6th.

On average, analysts expect that Puma Biotechnology will report full-year earnings of ($0.15) per share for the current year, with EPS estimates ranging from ($0.40) to $0.30. For the next financial year, analysts anticipate that the company will post earnings of $0.43 per share, with EPS estimates ranging from $0.02 to $1.00. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that that provide coverage for Puma Biotechnology.

Puma Biotechnology (NASDAQ:PBYI) last announced its earnings results on Wednesday, February 24th. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.07). The firm had revenue of $52.60 million during the quarter, compared to the consensus estimate of $52.31 million. Puma Biotechnology had a negative return on equity of 451.50% and a negative net margin of 23.86%.

Separately, Zacks Investment Research upgraded shares of Puma Biotechnology from a “sell” rating to a “hold” rating and set a $13.00 price target on the stock in a research report on Monday, February 15th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company’s stock. Puma Biotechnology presently has an average rating of “Hold” and a consensus price target of $12.57.

A number of hedge funds and other institutional investors have recently bought and sold shares of PBYI. Advisory Services Network LLC grew its position in Puma Biotechnology by 191.0% in the 4th quarter. Advisory Services Network LLC now owns 7,275 shares of the biopharmaceutical company’s stock worth $75,000 after purchasing an additional 4,775 shares during the last quarter. Raymond James & Associates acquired a new stake in shares of Puma Biotechnology during the 3rd quarter valued at about $111,000. ProShare Advisors LLC boosted its position in shares of Puma Biotechnology by 27.9% during the 4th quarter. ProShare Advisors LLC now owns 12,966 shares of the biopharmaceutical company’s stock valued at $133,000 after acquiring an additional 2,830 shares in the last quarter. Diversified Trust Co acquired a new stake in shares of Puma Biotechnology during the 4th quarter valued at about $141,000. Finally, Gyon Technologies Capital Management LP acquired a new stake in shares of Puma Biotechnology during the 4th quarter valued at about $144,000. Institutional investors own 87.90% of the company’s stock.

PBYI traded up $0.04 during trading on Monday, hitting $9.40. The stock had a trading volume of 1,428 shares, compared to its average volume of 380,676. The firm has a market cap of $378.43 million, a PE ratio of -6.55 and a beta of 1.39. Puma Biotechnology has a 12 month low of $7.26 and a 12 month high of $14.14. The company has a current ratio of 1.35, a quick ratio of 1.33 and a debt-to-equity ratio of 4.13. The company has a 50 day simple moving average of $10.62 and a 200-day simple moving average of $10.59.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous).

Featured Story: Stock Symbols and CUSIP Explained

Get a free copy of the Zacks research report on Puma Biotechnology (PBYI)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with's FREE daily email newsletter.